Why Amarin Trounced the Market on Tuesday
Amarin (NASDAQ: AMRN) rose to end Tuesday nearly 5.1% higher after the company provided details from clinical studies of the components of its one commercialized drug.
In a presentation at the American College of Cardiology's Annual Scientific Session, Amarin presented findings from a study of a key ingredient of that drug, cardiovascular treatment Vascepa (marketed as Vazkepa in the EU).
Image source: Getty Images.
Source Fool.com
